A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

BMJ Case Rep. 2018 Jun 28:2018:bcr2018225318. doi: 10.1136/bcr-2018-225318.

Abstract

Tumefactive appearing lesions on brain imaging can cause a diagnostic dilemma. We report a middle-aged man who presented with right-sided optic neuritis. A brain MRI showed enhancement of the right optic nerve, and non-enhancing white matter lesions including a 3 cm right frontal lesion with adjacent gyral expansion. Cerebrospinal fluid analysis showed five oligoclonal bands not present in serum. Glatiramer acetate was started for suspected tumefactive multiple sclerosis (MS). A follow-up brain MRI 6 months later showed persistence of the frontal gyral expansion. A brain biopsy led to the diagnosis of an oligodendroglioma, isocitrate dehydrogenase-mutant and 1 p/19q co-deleted (WHO grade II), managed with surgical resection and radiotherapy. Postoperative brain MRI showed a new enhancing periventricular lesion, making the choice of optimal disease-modifying therapy for MS challenging. This case highlights the possibility of coexistence of MS and oligodendroglioma, and emphasises the importance of a tissue diagnosis when atypical MS imaging features are present.

Keywords: multiple sclerosis; neuroimaging; neurooncology.

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Brain / diagnostic imaging*
  • Brain / pathology
  • Comorbidity
  • Craniotomy
  • Follow-Up Studies
  • Glatiramer Acetate / therapeutic use
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Multiple Sclerosis / diagnostic imaging*
  • Multiple Sclerosis / physiopathology
  • Multiple Sclerosis / therapy
  • Oligodendroglioma / diagnostic imaging*
  • Oligodendroglioma / physiopathology
  • Oligodendroglioma / therapy
  • Optic Neuritis / etiology*
  • Optic Neuritis / physiopathology
  • Radiotherapy
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Glatiramer Acetate